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Abstract
Background: To investigate alteration of high density lipoproteins (HDL) subclasses distribution in different total
cholesterol (TC) levels, mainly the characteristics of HDL subclasses distribution in desirable TC levels and analyze
the related mechanisms.
Methods: ApoA-I contents of plasma HDL subclasses were determined by 2-dimensional gel electrophoresis
coupled with immunodetection. 486 Chinese Adults subjects were assigned to different TC groups according to
the third Report of NCEP (ATP- III) guidelines.
Results: The increase in contents of small preb1-HDL, HDL3c, HDL3b, and HDL3a particles clustered and reduce in
HDL2b with increased of TC. The distribution of HDL subclasses have shown abnormality characterized by the lower
HDL2b (324.2 mg/L) contents and the higher preb1-HDL (90.4 mg/L) contents for desirable TC Chinese subjects.
Among 176 desirable TC subjects, 58.6% subjects with triglyceride (TG) < 2.26 mmol/L, 61.2% subjects with HDL-C
≥1.03 mmol/L and 88.6% subjects with low density lipoprotein cholesterol(LDL-C) < 3.34 mmol/L, and the profile
of HDL subclasses distribution for above these subjects was reasonable.
Conclusions: The particles size of HDL subclasses shifted towards smaller with increased TC levels. The TC was
liner with HDL2b contents and those can be reduced 17 mg/L for 0.5 mmol/L increment in TC levels. The HDL
subclasses distribution phenotype was not expectation for Chinese Population with desirable TC levels. Thus, from
the HDL subclasses distribution point, when assessing the coronary heart disease(CHD) risk not only rely on the TC
levels, but also the concentrations of TG, HDL-C and LDL-C must considered in case the potential risk for desirable
TC subjects with other plasma lipids metabolism disorders.
Introduction
Cholesterol is a fat-like substance used to help build cell
membranes, make some hormones, and form bile secre-
tions that aid in digestion. cholesterol’s most important
job is to help carry fat through your blood vessels. Cho-
lesterol travels in the blood in distinct particles contain-
ing both lipid and proteins (lipoproteins). Classical
concepts of the regulation of plasma cholesterol levels
involve roles for the “forward” delivery of low density
lipoprotein cholesterol (LDL-C) from the liver to the
peripheral tissues, mediated by the LDL receptor, and a
“reverse” delivery of cholesterol in the form of high den-
sity lipoproteins (HDL) from the peripheral tissues to
the liver [1]. The amount of HDL and LDL in the blood
is added together, this number for all practical purposes,
indicates the amount of total cholesterol (TC).
LDL-C is the primary transport carrier of cholesterol
in the circulation. A broad base of evidence indicates
that elevations in LDL cholesterol are a direct cause of
atherosclerosis. Long-term elevations of LDL cholesterol
lead to a progressive accumulation of coronary athero-
sclerosis [2]. Thus, LDL-C is proposed to be more
highly associated with coronary heart disease (CHD) [3].
HDL-C normally makes up 20-30% of the TC and it
prevents the uptake of LDL-C at receptor sites in the
body and participates in the metabolism of other lipo-
proteins. Strong epidemiological evidence links low
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bidity and mortality. High HDL-C levels conversely con-
vey reduced risk [4-6]. Epidemiological data taken as a
whole signify that a 1 percent decrease in HDL choles-
terol is associated with a 2-3 percent increase in CHD
risk.
HDL is highly heterogeneous, with subclasses that can
be identified on the basis of density, size, charge, and
protein composition [7] and using two-dimensional gel
electrophoresis coupled with immunoblotting, HDL can
be divided into large, cholesterol-rich (HDL2a and
HDL2b), small, lipid-poor (HDL3c,H D L 3b,H D L 3a,a n d
preb1-HDL) and preb2- H D L .W eh a v ep r e v i o u s l yi n v e s -
tigated the impact of plasma triglyceride (TG), TC,
LDL-C and HDL-C levels on HDL subclass distribution,
and found that the particle size of HDL shifted towards
smaller size as the rise of plasma TG, TC, LDL-C levels,
or the fall of HDL-C levels [8-11].
Thus, in this work, we mainly assessed that the effect
of TC levels on HDL subclasses distribution, especially
the characteristics of HDL subclasses distribution for
subjects with desirable TC levels [12].
Materials and methods
Subjects
Four hundred and eighty-six subjects, aged 33 to 78
years (56.1 ± 8.4), were recruited to participate in a
study examining plasma lipid and apolipoprotein con-
centrations. were recruited to participate in a study
examining plasma lipid and apo concentrations at West
China Medical Center, Sichuan University. These sub-
jects were from the Sichuan University and Sichuan
Normal University, in Chengdu, Sichuan province, PR
China, in which female were 198 and male were 288.
Exclusion criteria were the following: (1) the presence of
nephrosis, diabetes mellitus, hypothyroidism, or hepatic
impairment; (2) the presence of a major cardiovascular
event (myocardial infarction, severe or unstable angina
pectoris, and surgery) or stroke; (3) taking lipid-altering
medications; or (4) a history of alcohol abuse and smok-
ing cigarettes. Women who had undergone a hysterect-
omy with or without an oophorectomy were excluded
from the study, and for postmenopausal female subjects,
none were receiving hormone replacement therapy.
Informed consent was obtained from each subject upon
entry into the study population. This study protocol was
approved by the ethics committee.
To study the relationship between the TC levels and
HDL subclass distribution, we divided these subjects
into three subgroups using the Adult Treatment Panel
(ATP-III) guidelines for TC defined, that is, desirable
TC (<5.17 mmol/L), borderline-high TC (5.17-6.18
mmol/L), high TC (≥ 5.17 mmol/L) [12]. Moreover,
individuals were classified according to approximately
equal ninths of baseline TC for the entire study popula-
tion, and observed the levels of TC change and degree
of major HDL subclasses alteration.
Specimens
Whole blood specimens were drawn after a 12 hours
overnight fast into EDTA-containing tubes. Plasma was
separated within 1-2 hour. Plasma was stored at 4°C and
used for lipid and apo analyses within 24 hours. An ali-
quot of plasma was stored at -70°C for the determina-
tion of HDL subclasses.
Plasma lipid and apolipoprotein analyses
Plasma TG, TC and HDL-C concentrations were mea-
sured by the standard technique. TC and TG were
determined with enzymatic kits (Beijing Zhongsheng
Biotechnological Corporation, Beijing, and People’s
Republic of China). The HDL-C was determined after
precipitation of the apoB-containing lipoproteins by
phosphotungstate/magnesium chloride [13]. LDL-C was
calculated using the Friedwald formula (TG < 4.52
mmol/L) [14]. When plasma TG was at least 4.52
mmol/L, LDL-C was determined following the precipita-
tion method with polyvinylsulfate (enzymatic kits).
Plasma apoA-I, B-100, C-II, and C-III were determined
by radial immunodiffusion methods [15] using kits
developed at the Apolipoprotein Research Laboratory,
West China Medical Center, Sichuan University. The
intraassay coefficient of variation for apo concentrations
was between 2.1% and 4.8%; the interassay coefficient of
variation was 3.5% to 7.9% [16].
High density lipoprotein cholesterol subclass analysis
ApoA-I-containing HDL subclasses were measured by
nondenaturing two-dimensional gel electrophoresis asso-
ciated with the immunodetection method, as described
previously [17]. Briefly, 10 μl of plasma was first sepa-
rated by charge on 0.7% agarose gel into preb and a
mobility particles. In the second dimension, the two
fractions of HDL were further separated according to
size by 2-30% nondenaturing polyacrylamide gradient
gel electrophoresis. To determine HDL subclasses, Wes-
tern blotting was conducted after 2-D gel electrophore-
tic, plasma proteins and molecular markers were
electroretically transferred to PVDF membranes, stained
with 0.1% ponceau S, and the position of molecular
standard protein bands labeled by pencil, and destained
by diffusion, then using 5% bovine serum albumin(BSA)
recovered the membrane, following interaction with
horseradish peroxidase (HRP)-labeled goat antihuman
apo A-I immunoglobulin G. The HDL particle sizes
were calibrated using a standard curve that included
bovine serum albumin, ferritin and thyroglobulin (Phar-
macia, Uppsala, Sweden). The calculation of the relative
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sity of the electrophoresis spots. Then, the apoA-I con-
tents (in milligrams per liter) of the HDL subclasses
were calculated by multiplying the percentage of each
subclass by the plasma total apoA-I concentrations. The
interassay coefficients of variation of the relative concen-
tration of preb1-HDL, preb2-HDL, HDL3c,H D L 3b,
HDL3a,H D L 2a,a n dH D L 2b in the plasma sample were
9.4%, 9.8%, 4.9%, 6.2%, 7.3%, 11.1% and 7.9%, respec-
tively (n = 5).
Statistical analysis
Kolmogorov-Smirnov statistics was used to test nor-
mality of distributions of plasma lipids and HDL sub-
classes. For analysis, non-Gaussian-distributed data
were transformed using the natural logarithm to
approach a Gaussian distribution. All statistical ana-
lyses were performed using the statistical package
SPSS Version 13.0 (SPSS, Chicago, IL). Data in the
tables are expressed as mean ± S.D. The Duncan post-
hoc test was used in situations in which a significant
group (one-way analysis of variance) effect was
observed. Two-way ANOVA was performed to evalu-
ate the interactive effects of TG and TC on HDL sub-
classes distribution. Pearson correlation coefficients
were calculated to quantitatively analyze the associa-
tions among variables adjusted for TG concentration.
In all comparisons, P less than 0.05 (2-sided) repre-
sented a statistically significant difference.
Results
Relations of the preb1-HDL and HDL2b contents and
change in the levels of TC
To investigate the degree of major HDL subclasses
change with the levels of TC, varied, we divided the
levels of TC into 9 strata and using each stratum TC
median value as x axis, with every stratum TC corre-
sponding the median preb1-HDL and HDL2b contents
as y axis to plot (Figure 1). The figure shows associa-
tions of TC levels with decreased HDL2b contents.
The concentrations of plasma lipids, lipoproteins, and
apolipoproteins along with their ratios among subjects
categorized by TC concentration
Table 1 reports baseline demographic and plasma levels
of lipids, lipoproteins, and apolipoproteins as well as
their ratios for subjects in each TC subgroup. Subjects
in desirable and borderline-high TC subgroups were
somewhat younger than those included in high TC sub-
group. Concentrations of TG, TC, LDL-C, HDL-C, and
apoB-100, C-II, C-III along with the ratios of TC/HDL-
C, LDL-C/HDL-C and apoB-100/A-I were substantially
lower in desirable and borderline-high TC subgroups
than those in high TC subgroup.
The apolipoprotein A-I contents of HDL subclasses
according to the TC concentration
Table 2 displays the characteristics of HDL subclasses
contents for subjects in per TC subgroup. We observed
Figure 1 Relations of the preb1-HDL and HDL2b contents to the levels of TC.
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HDL3c,H D L 3b,a n dH D L 3a particles clustered with the
increases in TC concentration. When compared with
the subject in high TC subgroup, the subjects in both
borderline-high and desirable TC subgroups had higher
contents of large HDL2a and HDL2b particles. However,
large sized HDL2 particles kept the lower levels for sub-
jects in desirable TC subgroup.
Frequency distribution of the subjects according to the
concentrations of TG and HDL-C for subjects with
desirable TC levels
To further understand the profile of HDL subclasses
distribution in different levels of TG and HDL-C for
subjects with desirable TC, we using the ATP-III set the
1.03, 1.52 mmol/L for HDL-C and 2.26 mmol/L for TG
as cut-points to divided these subjects (Figure 2).
Figure 2 presented that there were 51 subjects (29.1%)
with TG ≥ 2.26 mmol/L-HDL-C < 1.03 mmol/L, and
only 14.8% (26) subjects with TG < 2.26 mmol/L-HDL-
C ≥ 1.55 mmol/L in desirable TC levels. Moreover, in
the desirable TC levels, the subjects with TG ≥ 2.26
mmol/L occupied approximately 41.4%, and 38.8% sub-
jects with HDL-C < 1.03 mmol/L.
The apolipoprotein A-I contents of HDL subclasses
according to the TG or HDL-C concentrations in desirable
TC subjects
As shown in Table 3, in desirable TC subjects, the con-
tents of preb1-HDL, HDL3b,a n dH D L 3a in TG < 2.26
Table 1 The concentrations of plasma lipids, lipoproteins, and apolipoproteins their ratios among subjects categorized
by TC levels
Desirable TC
(n = 176)
Borderline high-TC
(n = 194)
High TC
(n = 116)
Age(yr) 54.9 ± 8.3 57.2 ± 9.3
a‡ 58.6 ± 9.2
a§
BMI(kg/m
2) 23.3 ± 2.4 23.8 ± 2.3 23.2 ± 2.9
a§ b§
TG(mmol/L) 1.9 ± 0.2 2.2 ± 0.4 2.4 ± 0.5
a‡
TC(mmol/L) 4.6 ± 0.4 5.6 ± 0.3
a‡ 6.8 ± 0.4
a§ b‡
LDL-C(mmol/L) 2.5 ± 0.4 3.3 ± 0.6
a‡ 4.4 ± 0.7
a§b*
HDL-C(mmol/L) 1.1 ± 0.2 1.2 ± 0.3 1.3 ± 0.4
a*
ApoA-I(mg/L) 1210.7 ± 168.6 1282.2 ± 179.1 1280.8 ± 171.6
ApoB-100(mg/L) 769.6 ± 96.4 925.3 ± 108.3
a‡ 1081.4 ± 128.2
a§ b‡
ApoC-II(mg/L) 55.1 ± 10.3 70.1 ± 12.7
a* 79.2 ± 11.8
a*
ApoC-III(mg/L) 129.1 ± 20.6 157.5 ± 22.6
a* 180.2 ± 32.6
a§b*
TG/HDL-C 2.0 ± 0.3 2.2 ± 0.2 2.2 ± 0.3
TC/HDL-C 4.2 ± 1.0 5.0 ± 1.0
a‡ 5.5 ± 1.1
a§b*
LDL-C/HDL-C 2.3 ± 0.4 2.9 ± 0.7
a* 3.5 ± 0.9
a§b‡
ApoB-100/A-I 0.7 ± 0.2 0.7 ± 0.2 0.9 ± 0.3
a* b*
Values are expressed as Mean ± S.D
aCompared with Desirable TC
bCompared with Borderline high-TC
*P < 0.05,
‡P < 0.01,
§P < 0.001
TC, total cholesterol; BMI, body mass index; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; ApoA-I, B-100,
C-II, C-III, apolipoproteinA-I, B-100, C-II, C-III.
Table 2 The apoA-I contents of HDL subclasses among the subjects according to the TC levels
Desirable TC
(n = 176)
Borderline high-TC
(n = 194)
High TC
(n = 116)
Preb1-HDL(mg/L) 90.4 ± 15.3 102.2 ± 20.8 135.8 ± 24.9
a§b*
Preb2-HDL(mg/L) 53.5 ± 8.4 63.4 ± 9.1 70.0 ± 11.6
a*
HDL3c(mg/L) 69.1 ± 7.6 73.9 ± 8.6 82.7 ± 10.5
HDL3b(mg/L) 135.9 ± 21.5 145.6 ± 22.3 172.7 ± 28.6
a‡b*
HDL3a(mg/L) 281.9 ± 29.2 298.2 ± 24.2
a* 319.3 ± 30.1
a§b*
HDL2a(mg/L) 257.2 ± 20.1 259.9 ± 18.3 251.6 ± 21.5
HDL2b(mg/L) 324.2 ± 30.3 337.5 ± 35.3 281.7 ± 29.9
a§b§
Values are expressed as Mean ± S.D
aCompared with Desirable TC group
bCompared with Borderline high-TC group
*P < 0.05,
‡P < 0.01,
§P < 0.001
TC, total cholesterol; HDL3c, 3b, 3a, 2a, 2b, high density lipoproteins3c, 3b, 3a, 2a, 2b.
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2.26 mmol/L subgroup (P < 0.001). In contrast, those of
HDL2a and HDL2b in TG < 2.26 mmol/L subgroup were
significantly higher than TG ≥ 2.26 mmol/L subgroup
(P < 0.001). Likewise, compared to the subjects with
HDL-C < 1.03 mmol/L, the characteristics of HDL sub-
classes distribution in subjects with HDL-C ≥ 1.03
mmol/L was accord with that in subjects with TG <
2.26 mmol/L.
The apolipoprotein A-I contents of HDL subclasses
according to the LDL-C concentrations in desirable TC
subjects
Table 4 showed that in comparison with the subjects
with LDL-C < 3.34 mmol/L, the subjects with LDL-C ≥
3.34 mmol/L had higher contents of HDL3b,H D L 3a and
lower contents of HDL2a and HDL2b in desirable TC
levels.
Relationships among plasma lipids, lipoproteins,
apolipoproteins and HDL subclasses contents (Controlling
for TG)
After adjustment for TG, the TC concentration was
positively related to preb1-HDL, preb2-HDL, HDL3
(HDL3c,H D L 3b,a n dH D L 3a) and negatively related to
HDL2 (HDL2a and HDL2b). The relationship for LDL-C
and apoB-100 showed a significant positive with preb1-
HDL, HDL3c,H D L 3b but inverse with HDL2b.T h e
apoA-I levels were strong association with all HDL sub-
classes. Meanwhile, a significant correlation between the
preb1-HDL, HDL3c,H D L 3b,H D L 2 and HDL-C was
observed (Table 5). The 2-way ANOVA results indicated
Figure 2 Frequency distribution of subjects according to HDL-C together with TG levels.
Table 3 The apoA-I contents of HDL subclasses among the desirable TC subjects in accordance with TG along with
HDL-C levels
Desirable TC Desirable TC
TG < 2.26(n = 103) TG ≥ 2.26(n = 73) HDL-C < 1.03(n = 69) HDL-C ≥ 1.03(n = 107)
Preb1-HDL(mg/L) 79.3 ± 10.7 118.1 ± 21.4
§ 115.4 ± 11.5 83.1 ± 8.1
‡
Preb2-HDL(mg/L) 50.6 ± 8.1 56.1 ± 9.2 53.4 ± 4.2 54.5 ± 4.7
HDL3c(mg/L) 63.6 ± 8.6 72.2 ± 10.9 72.2 ± 8.4 64.0 ± 5.8
HDL3b(mg/L) 105.2 ± 28.9 146.9 ± 30.2
§ 146.5 ± 19.6 128.4 ± 17.4
HDL3a(mg/L) 258.2 ± 30.4 315.3 ± 40.9
§ 297.6 ± 28.9 274.1 ± 20.5*
HDL2a(mg/L) 268.6 ± 35.3 226.7 ± 29.7
§ 222.8 ± 20.7 272.6 ± 21.5
§
HDL2b(mg/L) 381.9 ± 50.5 242.8 ± 29.9
§ 247.6 ± 25.1 371.3 ± 40.6
§
Values are expressed as Mean ± S.D
Compared with the corresponding low levels group
*P < 0.05,
‡P < 0.01,
§P < 0.001
TC, total cholesterol; TG, triglyceride; HDL3c, 3b, 3a, 2a, 2b, high density lipoproteins3c, 3b, 3a, 2a, 2b.
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effect on preb2-HDL, HDL3c, HDL3b, HDL3a, and HDL2a
(Table 6).
Discussion
Numerous observational studies have demonstrated that
a strong, continuous, graded, and independent associa-
tion between cholesterol and the risk of CHD. A high
T Ci sam a r k e rf o ra t h e r o g e n i cl i p o p r o t e i n s .T h ee l e -
vated plasma TC contributes to coronary atherosclerosis
throughout life; which measured in young adulthood
correlate with CHD rates later in life and over a lifetime.
Increased lifetime risks associated with high TC levels (
≥ 6.21 mmol/L) are clearly evident and justify clinical
therapies to reduce long-term risk. But even borderline-
high TC (5.17-6.18 mmol/L) carries significant long-
term risk, and it deserves clinical intervention [18-22].
In this regard, only TC levels < 5.17 mmol/L was expec-
tation for Western people.
Population studies have shown a highly consistent,
inverse correlation between plasma concentrations of
HDL-C and atherosclerotic cardiovascular disease risk in
humans [23] and the concept that certain subfractions
of HDL may be better predictors of cardiovascular risk
is attractive [11]. Asztalos et al. [24] found that large a-
1 HDL (HDL2b) was most significantly associated with
CHD prevalence, and their study demonstrated that
each milligram per decaliter increase in a-1 HDL level
decreased the odds of CHD by 26% in a model includ-
ing all established CHD risk factors. Thus, HDL lipopro-
tein subfraction tests may be useful to help determine
the need to treat patients at intermediate risk for CHD
as determined by more conventional tests [25-32]. Epi-
demiological investigations have established that a high
level of LDL-C is a major risk factor for developing
CHD. For persons without other CHD risk factors, risk
for CHD is relatively low when LDL-C levels are <3.34
mmol/L. However, although the availability the effective
of LDL-C lowering therapies, many patients continue to
develop CHD and the contributions of other plasma
lipids and lipoprotein subclasses to the risk of CHD is
increasingly being recognized.
In current work, for grouped analyses, individuals
were classified according to approximately equal ninths
of baseline TC for the entire study population (Figure
1). Trends in mean values of major HDL subclasses
(preb1-HDL and HDL2b) across these ninths were
assessed through simple linear regression, in these mod-
els with the contents of preb1-HDL and HDL2b as the
dependent variable and the levels of TC as independent
variable. The Figure 1 showed that the levels of TC
were liner with HDL2b contents and HDL2b contents
can be reduced 17 mg/L for 0.5 mmol/L increment in
TC. At the same time, according to ATP-III guidelines,
the Chinese subjects were divided into desirable TC
(<5.17 mmol/L), borderline-high TC (5.17-6.18 mmol/
L), and high TC ( ≥ 6.21 mmol/L) groups, and observed
HDL subclasses distribution profile on different TC
levels that is the particles size of HDL subclasses shifted
towards smaller with increased TC levels. These findings
suggested that elevated TC blocked the maturation of
Table 4 The apoA-I contents of HDL subclasses among
the desirable TC subjects in accordance with LDL-C levels
Desirable TC
LDL-C < 3.34 (n = 156) LDL-C ≥ 3.34 (n = 20)
Preb1-HDL(mg/L) 84.3 ± 8.0 110.8 ± 8.2*
Preb2-HDL(mg/L) 50.8 ± 3.2 53.6 ± 3.7
HDL3c(mg/L) 59.1 ± 5.4 69.6 ± 6.1
HDL3b(mg/L) 135.3 ± 18.9 153.2 ± 20.1*
HDL3a(mg/L) 263.5 ± 26.9 282.8 ± 29.2*
HDL2a(mg/L) 288.1 ± 27.5 249.5 ± 20.4
§
HDL2b(mg/L) 370.6 ± 39.9 252.0 ± 30.8
§
Values are expressed as Mean ± S.D
Compared with the corresponding low levels group
*P < 0.05,
§P < 0.001
TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL3c, 3b, 3a,
2a, 2b, high density lipoproteins3c, 3b, 3a, 2a, 2b.
Table 5 The correlation analysis between lipids,
lipoproteins, and apoA-I contents of HDL subclasses
(Controlling for TG)
TC LDL-C HDL-C ApoA-I ApoB-100
t P t P t P t P t P
Preb1-HDL .390 .000 .381 .000 .063 .169 .491 .000 .183 .000
Preb2-HDL .136 .003 .077 .089 .165 .000 .489 .000 -.008 .867
HDL3c .217 .000 .156 .001 .193 .000 .360 .000 .112 .013
HDL3b .296 .000 .256 .000 .140 .002 .523 .000 .104 .022
HDL3a .091 .045 .075 .100 .058 .204 .567 .000 .045 .322
HDL2a -.130 .004 -.128 .005 .200 .000 .558 .000 -.031 .494
HDL2b -.136 .003 -.216 .000 .286 .000 .415 .000 -.168 .000
TG, triglyceride; TC, total cholesterol; LDL-C, low density lipoprotein
cholesterol, ApoA-I, B-100, apolipoproteinA-I, B-100; HDL3c, 3b, 3a, 2a, 2b, high
density lipoproteins3c, 3b, 3a, 2a, 2b.
Table 6 P values calculated by 2-way ANOVA for HDL
subclasses
Factor A
(TC)
Factor B
(TG)
Factor interaction
(TC × TG)
Preb1-HDL .000 .000 .000
Preb2-HDL .002 .042 .003
HDL3c .000 .192 .084
HDL3b .000 .369 .296
HDL3a .279 .001 .006
HDL2a .665 .000 .217
HDL2b .000 .000 .000
ANOVA, analysis of variance; TC, total cholesterol; TG, triglyceride; HDL3c, 3b, 3a,
2a, 2b, high density lipoproteins3c, 3b, 3a, 2a, 2b.
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cholesterol transport (RCT) might be impeded.
Numerous investigations have documented that in
hyperolesterolemic subjects, Lecithin:cholesterol acyl-
transferase (LCAT) activity was low while cholesterol
ester transport protein (CETP) activity was high, which
was associated with the increased plasma TC level in
these persons [33]. The activity of LCAT is required for
normal plasma lipoprotein structure and is instrumental
in HDL remodeling. LCAT may catalyze unesterified
cholesterol to cholesterol ester (CE) and promote the
conversion of preb1-HDL and HDL3 to HDL2.C E T Pi s
a plasma hydrophobic glycoprotein made by liver and
adipose that circulates in the plasma bound to lipopro-
teins. It mediates exchange of core lipids between very
low density lipoprotein (VLDL)-TG, LDL-TG and HDL-
CE. The net effect of CETP action on HDL is depletion
of CE and enrichment with TG, with an overall net
reduction in the size of HDL particles [34].
Furthermore, we surprisingly found the distribution of
HDL subclasses have shown abnormality characterized
by the contents of HDL2b (324.2 vs 379.9 mg/L)
decreased and the contents of preb1-HDL (90.4 vs 76.5
mg/L) increased significantly for desirable TC Chinese
subjects compared with those for normolipidemic Chi-
nese subjects in our previous study [9]. Why the distri-
bution of HDL subclasses has reversed for subjects in
desirable TC levels when the mean concentrations of
TG, TC, and LDL-C kept the relative normal range.
Our results exhibited that there were 103 subjects
with TG < 2.26 mmol/L and 107 subjects with HDL-C
≥ 1.03 mmol/L in the 176 desirable TC subjects as well
as the characteristic of distribution in HDL subclass dis-
tribution for these two groups subjects was consistent
with that for normolipidemic subjects [9]. On the con-
trary, profile of HDL subclass distribution for subjects
with TG ≥ 2.26 mmol/L showed a reduced in contents
of HDL2b (from 381.9 to 242.8 mg/L), but an increased
in contents of preb1-HDL (from 79.3 to118.1 mg/L)
compared to the subjects with TG < 2.26 mmol/L in
desirable TC levels. Similarly, the distribution of HDL
subclasses for subjects with HDL-C < 1.03 mmol/L
might be reversed characterized by small-sized preb1-
HDL elevated while large-sized HDL2 declined.
The decreased lipoprotein lipase (LPL) and phospholi-
pids transfer protein (PLTP) activities along with ele-
vated hepatic lipase (HL) activity are frequently
observed in higher TG levels and lower HDL-C levels.
LPL cleanses triglyceride-rich lipoproteins (TRL) from
circulation through its role in hydrolysis of TGs in chy-
lomicron (CM) and VLDL. PLTP favors the formation
of larger-sized HDL particles. Depletes the core of large
HDL2 by HL and helps to form smaller HDL3 as well as
lipid-free apoA-I and/or preb-HDL. In consequence of
the changes in activities of lipoprotein-modifying plasma
enzymes, which resulted in the particle size of HDL sub-
classes tend to small. Low levels of HDL-C and elevated
TG levels were associated with a high incidence of
CHD. For clinical purposes, low HDL-C (<1.03 mmol/L)
plus elevated TG (≥ 2.26 mmol/L) define atherogenic
dyslipidemia. The relationship between HDL-C and
CHD remained after adjustment for age and TG levels;
where even small differences in the level of HDL-C are
associated with substantial variations in the risk of
major coronary events. It has been documented that
cholesterol efflux is well correlated with plasma HDL-C
concentrations. Data from the Framingham population
indicated that, at any given level of TC, the relative risk
of CHD increases with decreasing levels of HDL-C [35].
Asztalos et al.[24] considered that altered HDL sub-
classes in low HDL-C subjects were prone to CHD by
RCT.
It is well known that the most common hyperlipide-
m i af o rt h eC h i n e s ep o p u l a t i o nw a sc h a r a c t e r i z e db y
elevated TG levels (ie, hypertriglyceridemia [HTG]). Our
previous study displayed that HTG accounted for about
61% of total hyperlipidemia [11]. Liu suggested that
HTG in China was induced by high-carbohydrate diets
of the populations. High-carbohydrate diets may result
in increased concentration of plasma glucose and, thus,
high-insulin levels. Hyperinsulinemia stimulates the pro-
duction and secretion of TG and VLDL, which lead to
HTG [36].
Because of the elevated TG concentrations usually not
only accompanied with reduced HDL-C, it also carried
increased LDL-C concentrations. Make use a cut-point
value of 3.34 mmol/L for the LDL-C to further dichoto-
mize the Chinese subjects in desirable TC levels. The
data presented that about 20 subjects with LDL-C ≥
3.34 mmol/L in desirable TC levels, and the particle size
of HDL subclass for these subjects tend to small.
Increased levels of plasma LDL-C resulted in decreased
CETP activity might be explained the alteration of HDL
subclasses in subjects with LDL-C ≥ 3.34 mmol/L [37].
We also observed that among the 156 subjects with
LDL-C < 3.34 mmol/L, one third (52) subjects with TG
≥ 2.26 mmol/L-HDL-C < 1.03 mmol, and the contents
of HDL2b (215.0 mg/L) reduced significantly along with
those of preb1-HDL (122.7 mg/L) elevated significantly
for these subjects. Collectively these findings demon-
strated that distribution of HDL subclasses has reversed
in desirable TC levels, especially in Chinese population.
Conclusions
Briefly, the higher TC levels, the particles size of HDL
subclasses tend to small suggested that elevated TC
blocked the maturation of HDL subclasses metabolism
and impeded the efficiency of RCT. The TC was liner
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Page 7 of 9with HDL2b contents and HDL2b contents can be
reduced 17 mg/L for 0.5 mmol/L increment in TC
levels. The phenotype of HDL subclasses distribution
was not expectation for Chinese Population with desir-
able TC in accordance with the ATP-III guidelines for
TC levels. Thus, from the HDL subclasses distribution
point, when assessing the CHD risk not only rely on the
TC levels, but also the concentrations of TG, HDL-C
and LDL-C must considered in case the potential risk
for desirable TC subjects with other plasma lipids meta-
bolism disorders.
The abbreviations used are
HDL: high density lipoproteins; TC: total cholesterol; ATP-III: Adult Treatment
Panel-III; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; CHD:
coronary heart disease; HRP: horseradish peroxidase; IgG: immunoglobulin G;
ANOVA: analysis of variance; RCT: reverse cholesterol transport; LCAT: lecithin:
cholesterol acyltransferase; CETP: cholesterol ester transport protein; CE:
cholesterol ester; VLDL: very low density lipoprotein; LPL: lipoprotein lipase;
PLTP: phospholipids transfer protein; HL: hepatic lipase; TRL: triglyceride-rich
lipoproteins; CM: chylomicron; HTG: hypertriglyceridemia.
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